Chugai Pharmaceutical (4519) Q1 2025 earnings summary

Executive summary

• Revenue and profit increased significantly in Q1 2025, driven by strong overseas exports of in-house products, especially Hemlibra and Actemra, with revenue up 21.8% and operating profit up 36.6% year-on-year.

• Domestic sales remained flat due to NHI drug price revisions and generics, but new and main products like Phesgo and PiaSky offset declines.

• Operating margin reached 48.4%, reflecting high profitability.

• Other revenue declined year-over-year due to reduced one-time income, despite higher Hemlibra-related income.

• The company is advancing its pipeline, including NXT007 (next-gen Hemlibra), orforglipron (oral GLP-1 agonist), and trontinemab (Alzheimer's), with several regulatory submissions and trial initiations planned.

Financial highlights

• Q1 2025 revenue: ¥288.5 billion (+21.8% YoY); operating profit: ¥139.5 billion (+36.6% YoY); net income: ¥99.2 billion (+30.6% YoY); EPS: ¥60.30 (+30.6% YoY).

• Overseas sales surged 54.7% YoY to ¥156.7 billion, mainly from Hemlibra and Actemra exports; domestic sales stable at ¥103.0 billion (-0.2% YoY); other revenue fell 11.7% YoY to ¥28.7 billion.

• Cost-to-sales ratio improved by 1.8 points to 33.7% due to a favorable product mix.

• Operating margin increased to 48.4% (up 5.3 pts YoY).

• Positive FX impact: ¥12.3 billion on revenue, ¥11.8 billion on operating profit, mainly due to yen depreciation against the Swiss franc.

Outlook and guidance

• Full-year revenue forecast: ¥1,190.0 billion; operating profit: ¥570.0 billion; net income: ¥410.0 billion; EPS: ¥250.00.

• Q1 progress toward full-year guidance: revenue 24.2%, operating profit 24.5%, net income 24.2%.

• Year-on-year growth expected for the full fiscal year, with continued global expansion of in-house products.

• Performance is on track with initial projections, with both revenue and operating profit progressing ahead of last year.

• Uncertainties remain regarding U.S. tariffs, biosimilar launches, and regulatory changes, but management is monitoring closely.